Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920

202147 citationsJournal Articlehybrid Open Access

Authors

Hamid Emamekhoo · University of Wisconsin–Madison

Mark R. Olsen · Oklahoma Cancer Specialists and Research Institute

Bradley Curtis Carthon · Emory University Hospital Midtown

Alexandra Drakaki · UCLA Health

Ivor Percent · Florida Cancer Specialists & Research Institute

Ana M. Molina · Cornell University

Daniel C. Cho

Abstract

In patients who had previously untreated aRCC and brain metastases-a population with a high unmet medical need that often is underrepresented in clinical trials-the approved regimen of NIVO + IPI followed by NIVO showed encouraging antitumor activity and no new safety signals.

Topics & Keywords

Cancer Immunotherapy and Biomarkers Renal cell carcinoma treatment Brain Metastases and Treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Cancer

Volume 128, Issue 5, pp. 966-974

DOI: 10.1002/cncr.34016

Field-Weighted Citation Impact: 3.04